Market Place
Sourcing Support
Kira Presents Long-Term KP104 PNH Phase 2 Results At EHA
16 May 2024 //
PR NEWSWIRE
Kira Presents Positive Results of KP104 Phase 2 Study in Patients with PNH
14 Dec 2023 //
PR NEWSWIRE
Kira gets clearance for bifunctional biologic trial in China, Australia
21 Dec 2022 //
CLINICALTRIALSARENA
Kira Announces First Cohort of Patients Dosed in Phase 2 Study of KP104
30 Nov 2022 //
PRNEWSWIRE
Kira to Present First-in-Human Clinical Data at Society for Nephrology Kidney
17 Oct 2022 //
PRNEWSWIRE
Kira Pharmaceuticals to Participate in Upcoming Investor Conferences
13 Oct 2022 //
PRNEWSWIRE
US FDA clears Kira’s IND application to begin PII trial of KP104
04 Oct 2022 //
PHARMABIZ
Kira to Present New Preclinical Data on Lead Asset KP104 at European Meeting
26 Aug 2022 //
PRNEWSWIRE
Kira Pharma Receives FDA ODD for KP104 for Paroxysmal Nocturnal Hemoglobinuria
28 Jul 2022 //
PRNEWSWIRE
Kira Pharmaceuticals Appoints Teri Loxam as COO & CFO
16 Nov 2021 //
PRNEWSWIRE
Kira Expands Executive Leadership Team with Chief Business Officer
23 Feb 2021 //
PRNEWSWIRE
Kira Announces First Participant Dosed in Phase 1 Clinical Trial for P014
02 Feb 2021 //
PRNEWSWIRE
Kira Announces First Participant Dosed in Phase 1 Clinical Trial for P014
02 Feb 2021 //
PRNEWSWIRE
Kira and its complement-target inhibitors plot run to the clinic investor cash
07 Jan 2021 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.